Copy to clipboard 
RIVANNA was granted FDA 510(k) clearance to market the Accuro XV Diagnostic Ultrasound System.
The clearance comes as RIVANNA accelerates development of AI-enabled capabilities for the Accuro XV platform, including BoneEnhance, an image segmentation module for enhanced bone visualization, and CADe/x, the first computer-aided detection algorithm for automated fracture identification derived from volumetric ultrasound imaging.
The Accuro XV features a conformable three-dimensional volumetric ultrasound probe that automates large field-of-view image acquisition following initial patient positioning. The system’s motorized linear translation technology acquires B-mode images, a 10 cm scan extent; a compliant polyurethane stand-off medium creates a conformable patient contact surface to improve acoustic coupling with irregular anatomies. The cart-based system includes a touchscreen interface, an integrated battery pack for point-of-care mobility, and DICOM-compatible image archival workflows.
Accuro XV is a portable, small-footprint point-of-care volumetric ultrasound imaging system for musculoskeletal imaging. The system features a conformable three-dimensional probe that automates large field-of-view B-mode image acquisitions without ionizing radiation. With AI-enabled decision-assist capabilities advancing toward FDA clearance, Accuro XV will deliver BoneEnhance, a machine learning software module that segments musculoskeletal anatomy to support 3D visualization of skeletal structures, and a CADe/x software module that uses machine learning to assist clinicians in detecting fractures from volumetric ultrasound imaging to support triage decisions, including referral for additional radiographic imaging.
Source: RIVANNA
RIVANNA was granted FDA 510(k) clearance to market the Accuro XV Diagnostic Ultrasound System.
The clearance comes as RIVANNA accelerates development of AI-enabled capabilities for the Accuro XV platform, including BoneEnhance, an image segmentation module for enhanced bone visualization, and CADe/x, the first computer-aided detection...
RIVANNA was granted FDA 510(k) clearance to market the Accuro XV Diagnostic Ultrasound System.
The clearance comes as RIVANNA accelerates development of AI-enabled capabilities for the Accuro XV platform, including BoneEnhance, an image segmentation module for enhanced bone visualization, and CADe/x, the first computer-aided detection algorithm for automated fracture identification derived from volumetric ultrasound imaging.
The Accuro XV features a conformable three-dimensional volumetric ultrasound probe that automates large field-of-view image acquisition following initial patient positioning. The system’s motorized linear translation technology acquires B-mode images, a 10 cm scan extent; a compliant polyurethane stand-off medium creates a conformable patient contact surface to improve acoustic coupling with irregular anatomies. The cart-based system includes a touchscreen interface, an integrated battery pack for point-of-care mobility, and DICOM-compatible image archival workflows.
Accuro XV is a portable, small-footprint point-of-care volumetric ultrasound imaging system for musculoskeletal imaging. The system features a conformable three-dimensional probe that automates large field-of-view B-mode image acquisitions without ionizing radiation. With AI-enabled decision-assist capabilities advancing toward FDA clearance, Accuro XV will deliver BoneEnhance, a machine learning software module that segments musculoskeletal anatomy to support 3D visualization of skeletal structures, and a CADe/x software module that uses machine learning to assist clinicians in detecting fractures from volumetric ultrasound imaging to support triage decisions, including referral for additional radiographic imaging.
Source: RIVANNA
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
